Your browser is no longer supported. Please, upgrade your browser.
Settings
LCTX Lineage Cell Therapeutics, Inc. daily Stock Chart
LCTX [AMEX]
Lineage Cell Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.40 Insider Own3.70% Shs Outstand149.81M Perf Week-3.45%
Market Cap116.87M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float140.86M Perf Month-25.92%
Income-59.40M PEG- EPS next Q-0.04 Inst Own42.80% Short Float5.52% Perf Quarter-2.45%
Sales3.10M P/S37.70 EPS this Y77.80% Inst Trans0.03% Short Ratio5.96 Perf Half Y-0.84%
Book/sh0.71 P/B1.07 EPS next Y5.90% ROA-44.90% Target Price- Perf Year-32.48%
Cash/sh0.17 P/C4.55 EPS next 5Y- ROE-50.60% 52W Range0.53 - 1.67 Perf YTD-14.27%
Dividend- P/FCF- EPS past 5Y31.90% ROI-27.80% 52W High-54.31% Beta2.13
Dividend %- Quick Ratio7.50 Sales past 5Y-7.70% Gross Margin85.90% 52W Low42.91% ATR0.06
Employees55 Current Ratio7.50 Sales Q/Q-44.40% Oper. Margin- RSI (14)37.26 Volatility4.54% 6.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-119.00% Profit Margin- Rel Volume0.48 Prev Close0.76
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume1.30M Price0.76
Recom2.20 SMA20-14.89% SMA50-16.47% SMA200-15.12% Volume0 Change0.00%
Jul-06-20 08:00AM  
Jun-25-20 08:00AM  
Jun-24-20 08:00AM  
Jun-18-20 08:00AM  
Jun-17-20 08:00AM  
Jun-11-20 08:00AM  
Jun-08-20 08:00AM  
Jun-01-20 08:00AM  
May-19-20 08:00AM  
May-07-20 04:05PM  
11:30AM  
08:00AM  
May-06-20 01:35PM  
09:05AM  
May-05-20 08:00AM  
Apr-30-20 01:19PM  
12:34PM  
Apr-29-20 08:00AM  
Apr-24-20 08:00AM  
Mar-26-20 06:18AM  
Mar-24-20 04:00PM  
Mar-12-20 06:55PM  
04:05PM  
02:30PM  
Mar-05-20 12:30PM  
08:00AM  
Feb-20-20 08:00AM  
Feb-18-20 08:00AM  
Feb-10-20 08:00AM  
Feb-06-20 08:00AM  
Jan-23-20 10:47AM  
Jan-16-20 12:00PM  
Jan-02-20 08:00PM  
Dec-30-19 08:00AM  
Dec-25-19 08:31PM  
Dec-24-19 08:00AM  
Dec-19-19 08:00AM  
Dec-10-19 08:00AM  
08:00AM  
Nov-15-19 08:00AM  
Nov-12-19 04:05PM  
Nov-05-19 08:00AM  
Oct-28-19 08:00AM  
Oct-23-19 08:00AM  
Oct-22-19 08:00AM  
Oct-14-19 01:45PM  
Oct-07-19 08:00AM  
Sep-30-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-23-19 08:00AM  
Sep-19-19 07:00AM  
Sep-11-19 09:15AM  
Sep-04-19 08:00AM  
Aug-26-19 08:00AM  
Aug-20-19 08:00AM  
Aug-13-19 08:00AM  
Aug-12-19 08:00AM  
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Culley Brian MPresident and CEOJun 30Option Exercise0.8715,45013,442170,731Jul 02 05:05 PM
Culley Brian MPresident and CEOMar 31Option Exercise0.8315,45012,794160,624Mar 31 08:00 PM
Lineage Cell Therapeutics, IncPrevious 10% OwnerJan 02Sale2.162,383,0905,137,9426,041,154Jan 06 05:00 PM
Culley Brian MPresident and CEODec 31Option Exercise0.0015,4500150,517Dec 31 05:00 PM